 <h1>Tbo-filgrastim Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of tbo-filgrastim include:</b> hyperuricemia, increased lactate dehydrogenase, increased leukocyte alkaline phosphatase, increased serum alkaline phosphatase, ostealgia, and thrombocytopenia. <b>Other side effects include:</b> arthralgia, headache, myalgia, and pruritus.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tbo-filgrastim: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, tbo-filgrastim may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking tbo-filgrastim:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>bone pain</li>
<li>fever</li>
<li>pinpoint red spots on the skin</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Chills</li>
<li>cough</li>
<li>eye pain</li>
<li>general feeling of illness</li>
<li>headache</li>
<li>sore throat</li>
<li>unusual tiredness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blisters or fever sores on the skin</li>
<li>bloody or cloudy urine</li>
<li>chest pain or tightness</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>hives, itching, or skin rash</li>
<li>pain in the upper left part of the stomach or at the tip of the left shoulder</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>trouble breathing</li>
<li>unusual weakness</li>
<li>weight gain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of tbo-filgrastim may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>pain in the arms or legs</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>lack or loss of strength</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tbo-filgrastim: subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (up to 34%)</p>
<p><b>Frequency not reported</b>: Aortitis, capillary leak syndrome</p><p>In a clinical trial, thrombocytopenia occurred in 34% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.</p><h3>Gastrointestinal</h3><p>In a clinical trial, diarrhea occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea</p>
<p><b>Frequency not reported</b>: Vomiting<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Bone pain, extremity pain</p>
<p><b>Frequency not reported</b>: Myalgia<sup>[Ref]</sup></p><p>In a clinical trial, extremity pain occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.<sup>[Ref]</sup></p><h3>Other</h3><p>In a clinical trial, pyrexia occurred in 8% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Pyrexia</p>
<p><b>Postmarketing reports</b>: Asthenia, fatigue<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p>In a clinical trial, headache occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.</p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Anti-drug antibodies to this drug</p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Fatal splenic rupture, leukocytosis, sickle cell disorders<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Cutaneous vasculitis</p>
<p><b>Postmarketing reports</b>: Acute febrile neutrophilic dermatosis, Sweet's syndrome<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Potential for tumor growth stimulatory effects on malignant cells</p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Serious allergic reactions</p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Acute respiratory distress syndrome</p><h3>Renal</h3><p><b>Frequency not reported</b>: Glomerulonephritis</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about tbo-filgrastim</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: colony stimulating factors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tbo-filgrastim Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Granix</dd></dl>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Neutropenia Associated with Chemotherapy</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tbo-filgrastim: subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (up to 34%)</p><p><b>Frequency not reported</b>: Aortitis, capillary leak syndrome</p><p>In a clinical trial, thrombocytopenia occurred in 34% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.</p><h3>Gastrointestinal</h3><p>In a clinical trial, diarrhea occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea</p><p><b>Frequency not reported</b>: Vomiting<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Bone pain, extremity pain</p><p><b>Frequency not reported</b>: Myalgia<sup>[Ref]</sup></p><p>In a clinical trial, extremity pain occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.<sup>[Ref]</sup></p><h3>Other</h3><p>In a clinical trial, pyrexia occurred in 8% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Pyrexia</p><p><b>Postmarketing reports</b>: Asthenia, fatigue<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p>In a clinical trial, headache occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.</p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Anti-drug antibodies to this drug</p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Fatal splenic rupture, leukocytosis, sickle cell disorders<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Cutaneous vasculitis</p><p><b>Postmarketing reports</b>: Acute febrile neutrophilic dermatosis, Sweet's syndrome<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Potential for tumor growth stimulatory effects on malignant cells</p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Serious allergic reactions</p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Acute respiratory distress syndrome</p><h3>Renal</h3><p><b>Frequency not reported</b>: Glomerulonephritis</p><p id="ref_1">1. "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA. </p><h2>More about tbo-filgrastim</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: colony stimulating factors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tbo-filgrastim Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Neutropenia Associated with Chemotherapy</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>